姜涛 北京安定医院是一家北京市属三级甲等精神专科医院，医院创建于1908年。姜涛医生1993年入职安定医 院，目前从事精神科临床已有三十余年，担任精神科病房主任二十余年。 精神科医生和社会学家、记者有一个共同点，都是琢磨"人"。姜涛在多年行医的过程中积累了大量临床 诊疗病例，主要在精神分裂症、双相情感障碍、抑郁症、焦虑症、睡眠障碍以及酒药物成瘾等多个精神 科常见疾病方面有丰富的诊疗经验。 据姜涛介绍，上世纪九十年代以来，我国精神医学和精神疾病治疗发展历程的第一个重要节点是1997年 第二代抗精神病药物上市。当时精神病院主要针对精神分裂症患者，此后治疗从单纯症状控制转向强调 患者功能恢复，从长期住院护理模式转变为社区或家庭康复。从2002年起，特别是"非典"之后，北京安 定医院开展了北京市抑郁症流行病学调查，2005年结果显示，北京市十五岁以上人群抑郁症患病率超过 百分之六。全社会开始迅速关注抑郁症、焦虑症、双相情感障碍、强迫症和躯体化障碍等情绪相关疾 病。与此同时，中国精神病诊疗体系逐渐与世界发达国家接轨，在某些领域超过世界平均水平。2012年 后，儿童青少年的抑郁、焦虑、发育问题以及与上学相关的情绪行为问题 ...

Core Insights - Lijun Group reported a revenue of 3.181 billion yuan for Q1 2025, a year-on-year decrease of 1.92%, while net profit reached 637 million yuan, reflecting a year-on-year increase of 4.75% [1] - The growth in net profit marks a continued trend of stable growth for the company over several years [1] Product Performance - Key contributors to the company's performance include products for mental and gastrointestinal diseases [1] - In the mental health sector, Lijun Group has developed a product matrix covering common conditions such as schizophrenia and depression, with core products including Ruili (fluvoxamine) and Kanger (paliperidone), both recognized as first-line treatments in authoritative guidelines [1] - Additional products like Litingxin (bupropion), Shulida (lurasidone), and Ruisi Tuo (quetiapine) form a multi-target, multi-mechanism treatment network, providing personalized treatment options for patients with schizophrenia and bipolar disorder [1] Research and Development Pipeline - Lijun Group's R&D pipeline is characterized by a complete and well-structured approach in the mental health field [2] - The company is addressing difficult-to-treat conditions with innovative targets, such as NS-041, which shows promise for drug-resistant epilepsy and severe depression [2] - Long-acting formulations, including injectable aripiprazole microspheres and paliperidone palmitate, are being developed to improve patient compliance [2] - NS-041, a new generation KCNQ2/3 activator, is expected to enter Phase II clinical trials, with potential applications extending to severe depression, bipolar disorder, neuropathic pain, and amyotrophic lateral sclerosis [2] - The company anticipates approval for its significant schizophrenia treatment, aripiprazole microspheres, in the near future [2]